Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lamivudine
Drug ID BADD_D01242
Description A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Indications and Usage For the treatment of HIV infection and chronic hepatitis B (HBV).
Marketing Status approved; investigational
ATC Code J05AF05
DrugBank ID DB00709
KEGG ID D00353
MeSH ID D019259
PubChem ID 60825
TTD Drug ID D07TQV
NDC Product Code 65015-756; 49702-203; 60687-362; 53873-075; 49702-205; 69097-167; 42385-714; 52482-003; 70966-0036; 0173-0663; 65862-055; 60505-3252; 65862-026; 69097-166; 53873-073; 55773-0589; 68554-0043; 31722-001; 49702-204; 64380-710; 68554-0016; 31722-752; 31722-754; 50742-624; 60687-720; 64380-711; 68180-602; 53104-7677; 70159-001; 31722-753; 54838-566; 57237-274; 60429-354; 66993-478; 68180-603; 53104-7538; 65015-701; 67835-0017; 60505-3250; 0904-6583; 53873-074; 65862-577; 33342-001; 0173-0662; 60505-3251; 65862-259; 65862-025; 82245-0204; 33342-002; 50742-623; 60429-353
UNII 2T8Q726O95
Synonyms Lamivudine | 3TC | 2',3'-Dideoxy-3'-thiacytidine | 2',3' Dideoxy 3' thiacytidine | Epivir | Lamivudine, (2S-cis)-Isomer | BCH-189 | BCH 189 | BCH189 | GR-109714X | GR109714X
Chemical Information
Molecular Formula C8H11N3O3S
CAS Registry Number 134678-17-4
SMILES C1C(OC(S1)CO)N2C=CC(=NC2=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gait disturbance17.02.05.016; 08.01.02.002; 15.03.05.0130.003036%
Gastritis07.08.02.0010.001518%
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal infection11.01.07.012; 07.19.02.005--Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.0040.001012%
Gingival bleeding24.07.02.010; 07.09.07.001--Not Available
Graft versus host disease12.02.09.001; 10.02.01.0270.001518%Not Available
Groin pain15.03.02.0040.001012%Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Haemoglobin13.01.05.018--Not Available
Haemothorax12.01.18.005; 24.07.01.008; 22.05.02.0010.001518%
Hallucination, auditory19.10.04.0040.001012%Not Available
Headache17.14.01.001--
Hemiparesis17.01.04.0010.001012%
Hepatic cirrhosis09.01.04.0010.001012%Not Available
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.001518%Not Available
Hepatic failure09.01.03.0020.003036%
Hepatic fibrosis24.08.06.002; 09.01.04.0020.001012%Not Available
Hepatic function abnormal09.01.02.0010.009107%Not Available
Hepatic steatosis14.08.04.005; 09.01.07.003--Not Available
Hepatitis09.01.07.0040.004048%Not Available
Hepatitis acute09.01.07.0050.004048%Not Available
Hepatitis B11.05.28.003; 09.01.09.003--
Hepatitis C11.05.28.004; 09.01.09.005--Not Available
Hepatocellular injury09.01.07.0080.001518%Not Available
Hepatomegaly09.01.05.001--Not Available
Hepatorenal syndrome20.01.03.012; 09.01.03.0070.001012%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.007083%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 13 Pages